Tanios S. Bekaii-Saab, MD, discusses FIGHT-302 data showing frontline pemigatinib significantly improves PFS in FGFR2-positive cholangiocarcinoma.
Emerging Data Advancing Precision Medicine Across GI Malignancies From ASCO 2026
Zev A. Wainberg, MD, discusses the rapidly evolving landscape of KRAS-directed therapy in PDAC from pan-RAS inhibition to KRAS G12D–specific strategies.
Marwan G. Fakih, MD, discusses how data from the POD1UM-303 trial support the use of retifanlimab in frontline squamous cell anal carcinoma.
Marwan G. Fakih, MD, discusses how updated OS data from POD1UM-303 cement frontline retifanlimab plus chemotherapy as the standard of care in advanced SCAC.
Pemigatinib improved PFS as first-line therapy for FGFR2-rearranged cholangiocarcinoma in the phase 3 FIGHT-302 trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5